TABLE 2.—SHORT-TERM TOXICITY STUDIES SCHEDULED FOR REVIEW BY THE NTP BOARD OF SCIENTIFIC COUNSELORS' TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM APRIL 1996 THROUGH 1998—Continued

Chemical name/CAS No.	Use	Route	Species	Exposure levels
Short-Term Toxicity Studies Tentatively Scheduled for Peer Review May 1996:				
M-Chloroaniline:				
108–42–9	INTR	GAV	RM	R&M 0, 10, 20, 40, 80, 160 43 mg/kg, 20/grp (rats); 10/grp (mice).
O-Chloroaniline:				
95–51–2	DYE	GAV	RM	R&M 0, 10, 20, 40, 80, & 160 43 mg/kg, 20/grp (rats); 10/grp (mice).
Short-Term Toxicity Studies Tentatively Scheduled for Peer Review June 1996:				
AZT+Methadone HCL (AIDS):				
Aztmethcomb	PHAR	GAV	MM	AZT: 200, 400, or 800 mg/kg/day with Methadone HCL: 5, 15, or 30 mg/kg/day.
2′, 3′-Dideoxycytidine (AIDS initiative):				
7481–89–2	PHAR	GAV	MM	Female mice only: 500, 1000 mg/kg/day.
3, 3′, 4, 4′-Tetrachloroazobenzene:				
14047–09–7	HERB	GAV	RM	R&M: 0, 0.1, 1.0, 3.0, 10, or 30 mg/kg body weight (M&F; 10/group).
1, 1, 2, 2-Tetrachloroethane	SOLV	GAV	RM	
1, 1, 2, 2-Tetrachloroethane:				
79–34–5	SOLV	MICRO	RM	R&M; R:untreated control, vehicle control, 18, 37, 75, 150, or 300 mg/kg body wt/day; M: untreated control, vehicle control, 88, 175, 350, 700, or 1400 mg/kg body wt/day; 10/group/sex.
Short-Term Toxicity Studies Tentatively Scheduled for Peer Review August 1996:				
1, 1, 1-Trichloroethane:				
71–55–6	SOLV	MICRO	RM	R&M: 0, 0.5, 1.0, 2.0, 4.0, 41 and, 8.0% (10/S/S).
Short-Term Toxicity Studies Tentatively Scheduled for Peer Review December 1996:				
CIS & TRANS 1,2-Dichloroethylene:				
540–59–0	SOLV	MICRO	RM	55.
CIS-1, 2-Dichloroethylene:				
156–59–2	SOLV	MICRO	RM	55.
TRANS-1, 2-Dichloroethylene:				
156–60–5	SOLV	MICRO	RM	55.
TRANS-1, 2-Dichloroethylene:				
156–60–5	SOLV	GAV	RM	55.
TRANS-1, 2-Dichloroethylene:				
156–60–5	SOLV	MICRO	RM	R&M: untreated control, vehicle control, 3125, 6250, 12,500, 25,000, or 50,000 ppm; 10/group/sex.

Abbreviations used: in this report:

Use	Primary use category
COMT	Contaminates and/or Impurities.
COSM	Cosmetics, Perfumes, Fragrances, Hair Preparations.
DTRG	Detergents and Cleaners.
DYE	As or in Dyes, Inks, and Pigments.
ELEC	In Electrical and/or Dielectric Systems.
FOOD	Food, Beverages, or Additives.
HERB	Herbicide(s).
INTR	Chemical Intermediate or Catalyst.
PEST	Pesticides, General or Unclassified.
PHAR	Pharmaceuticals or Intermediates.
PLAS	As or in Plastics.
PNT	Paint Ingredient.
RUBR	Rubber Chemical.
SOLV	Vehicles and Solvents.
TEXL	In Manufacture of Textiles.

Route	Route of administration
FEED	Dosed-Feed.
GAV	Gavage.
INHAL	Inhalation.
IP/IJ	Intraperitoneal Injection.
IVAG	Intravaginal.
MICRO	Microencapsulation in Feed.
SC&GV	Subcutaneous Inj.+Gavage.
SP	Topical.
WATER	Dosed-Water.
WB	Whole Body Exposure.

Spec		Species
R	=	Rats.
M	=	Mice.

[FR Doc. 96–14149 Filed 6–7–96; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a list of information collection requests under OMB review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these documents, call the SAMHSA Reports Clearance Officer on (301) 443–0525.

FY 1997/1998 Substance Abuse Prevention and Treatment Block Grant Application Format—Revision of a currently approved collection—The Public Health Service Act (42 U.S.C. 300x 1–9) authorizes block grants to States for the purpose of providing prevention and treatment services.

Under the provisions of the law, States may receive allotments only after an application is approved by the Secretary, DHHS. The uniform application format provides States with the forms and instructions for their applications so they can comply with the requirements of the law and regulations implementing the law. The annual burden estimate is shown below:

No. of respondents	No. of responses per respondent	Avg. burden per response	Total annual burden
60	1	561.5 hours.	33,690 hours.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Virginia Huth, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10236, Washington, DC 20503.

Dated: May 31, 1996.

Patricia S. Bransford,

Acting Executive Officer, Substance Abuse and Mental Health Services Administration.

[FR Doc. 96–14573 Filed 6–7–96; 8:45 am]

BILLING CODE 4162–20–P

Food and Drug Administration

Import and Private Laboratory Communities: Public Meetings

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public meetings.

SUMMARY: The Food and Drug Administration's (FDA's) Office of Regulatory Affairs (ORA) is announcing a series of Grassroots Meetings to be held with the import and private laboratory communities. These meetings will follow a prescribed format similar to what was used recently in the Grassroots Regulatory Partnership Meetings held as part of the National Performance Review and will be conducted by key agency officials including ORA's Division of Field Science, the Division of Import Operations and Policy, and other representatives from the field and headquarters.

The purpose of the meetings is to establish a dialogue with the import, domestic, and private laboratory communities, trade associations, and other interested persons. The intent of the dialogue is to explore ways the agency might improve current policy and procedures related to the use of private laboratories to establish product compliance with FDA regulations. After the meetings a report will be prepared outlining a strategy for making positive changes in policy and/or procedures related to the agency's use of analytical data from private laboratories.

DATES: The public meetings are scheduled as follows:

1. Tuesday, June 25, 1996, 9 a.m. to 4:30 p.m., Brooklyn, NY.
2. Friday, June 28, 1996, 9 a.m. to 4:30 p.m., Orlando, FL.
3. Tuesday, July 9, 1996, 9 a.m. to 4:30 p.m., Houston, TX.
4. Thursday, July 11, 1996, 9 a.m. to 4:30 p.m., Oakland, CA.

ADDRESSES: The public meetings will be held at the following locations:

1. Brooklyn—Fort Hamilton Community Club, 101st St. and Fort Hamilton Pkwy., Bldg. 207, Brooklyn, NY.
2. Orlando—Sheraton Plaza Hotel, 1500 Sand Lake Rd., Orlando, FL.
3. Houston—Houston Plaza Hilton, 6633 Travis St., Houston, TX.
4. Oakland—Oakland Federal Bldg., Edward Royball Auditorium, 1301 Clay St., Oakland, CA.

FOR FURTHER INFORMATION CONTACT:

Regarding attendance at the Brooklyn, NY public meeting: George Walden, Small Business Representative Northeast Region, 850 Third Ave., Brooklyn, NY 11232, 718–965–5300, ext. 5528 or FAX 718–965–5759.

Regarding attendance at the Orlando, FL public meeting: Barbara Ward-Groves, Small Business Representative Southeast Region, 60 Eighth St. NE., Atlanta, GA 30309, 404–347–4001, ext. 5256 or FAX 404–347–4349.

Regarding attendance at the Houston, TX public meeting: Marie T. Falcone, Small Business Representative Southwest Region, 7920 Elmbrook Dr., suite 102, Dallas, TX 75247–4982, 214–655–8100, ext. 128 or FAX 214–655–8130.

Regarding attendance at the Oakland, CA public meeting: Mark S. Roh, Small Business Representative Pacific Region, Oakland Federal Bldg., 1301 Clay St., suite 1180–N, Oakland, CA 94612–5217, 510–637–3980 or FAX 510–637–3977.

In addition to this public notice of the meetings, invitations will be sent directly to interested persons representing private laboratories, importers, brokers, independent samplers, scientific and trade associations, accreditation bodies, and domestic users of private laboratories.

Interested persons who have not received an invitation to attend one of these meetings by June 7, 1996, may contact the Small Business Representatives specified above for registration forms.

Persons who are unable to attend, or who cannot be accommodated due to space limitations are invited to provide written comments. Written comments may be submitted to Liza Lehman, Division of Field Science (HFC–140), 5600 Fishers Lane, rm. 12–41, Rockville, MD 20857. Issues submitted in writing will be included for discussion at the meetings and will appear in the final report.

Questions related to these meetings should be directed to Richard A. Baldwin or Liza Lehman (address above) or by calling 301–443–7103 between 8 a.m. and 4:30 p.m.

SUPPLEMENTARY INFORMATION: The following background information is provided for meeting participants. The term ''private laboratory'' refers to those private sector laboratories that conduct analysis on freely marketed, FDA regulated products whose analytical data is submitted to the agency in order to demonstrate a product's compliance with laws and regulations administered by FDA.

Meeting Objectives

(1) To establish a dialogue with the import, domestic, and private laboratory communities; trade associations; and other interested persons on ways the agency might improve current policy and procedures related to the use of private laboratories to establish product compliance with FDA laws and regulations.

(2) To obtain information and views from interested persons on ways the agency might enhance its use of private laboratories to facilitate getting products that comply with applicable laws and regulations to the consumer while removing non-compliant products from the marketplace.

The following workshops will be offered at each meeting:

Workshop I

Workshop I will focus on the following issues:

(1) What practices, procedures, or policies should be changed so that private sector testing expedites the removal of products that do not comply with FDA laws and regulations and the distribution of products that are fully compliant?

(2) What is FDA's experience with how the current process works?

(3) What needs to be changed about the current process?

(4) Why and how?